Table 1.
Demographic and clinical characteristics
| Number of patients | Total | No hyponatremia episode | ≥1 hyponatremia episode | P value |
|---|---|---|---|---|
| N = 1758 | n = 815 | n = 943 | ||
| Demographic characteristics | ||||
| Sex, n (%) | <0.01 | |||
| Male | 503 (29) | 145 (18) | 358 (38) | |
| Female | 1255 (71) | 670 (82) | 585 (62) | |
| Age group collapsed, n (%) | 0.06 | |||
| 18–64 | 1108 (63) | 533 (65) | 575 (61) | |
| ≥65 | 650 (37) | 282 (35) | 368 (39) | |
| Mean age (SD) | 60.2 (13) | 59.6 (13) | 60.6 (13) | 0.11 |
| Race, n (%) | 0.09 | |||
| Asian | 18 (1) | 8 (1) | 10 (1) | |
| Black | 340 (19) | 179 (22) | 161 (17) | |
| White | 1393 (79) | 627 (77) | 766 (81) | |
| Median household income, n (%) | 0.16 | |||
| ≤$49,999 | 1030 (59) | 480 (59) | 550 (58) | |
| $50,000–$69,999 | 460 (26) | 197 (24) | 263 (28) | |
| ≥$70,000 | 239 (14) | 123 (15) | 116 (12) | |
| Diagnosis year, n (%) | 0.02 | |||
| 2002–2004 | 270 (15) | 146 (18) | 124 (13) | |
| 2005–2007 | 869 (49) | 386 (47) | 483 (51) | |
| 2008–2010 | 619 (35) | 283 (35) | 336 (36) | |
| Mean length of follow-up, y (SD) | 3.1 (3) | 3.3 (3) | 3.0 (3) | 0.03 |
| Clinical characteristics at baseline | ||||
| Cancer type, n (%) | ||||
| Breast | 839 (48) | 533 (65) | 306 (32) | <0.01 |
| Colorectal | 233 (13) | 84 (10) | 149 (16) | <0.01 |
| Colon | 146 (8) | 50 (61) | 96 (10) | <0.01 |
| Rectal | 87 (5) | 34 (4) | 53 (6) | 0.16 |
| Lung | 485 (28) | 117 (14) | 368 (39) | <0.01 |
| Small cell | 80 (5) | 19 (2) | 61 (7) | <0.01 |
| Non-small cell | 405 (23) | 98 (12) | 307 (33) | <0.01 |
| Lymphoma | 201 (11) | 81 (10) | 120 (13) | 0.07 |
| Hodgkins | 29 (2) | 12 (2) | 17 (2) | 0.59 |
| Non-Hodgkins | 172 (10) | 69 (9) | 103 (11) | 0.08 |
| Distant metastasis, n (%) | 384 (22) | 99 (12) | 285 (30) | <0.01 |
| Any PS within 90 days of diagnosis, n (%) | 864 (49) | 384 (47) | 480 (51) | 0.11 |
| Grade 1: ECOG 0, 1; KPS 80–100a | 747 (87) | 350 (91) | 397 (83) | <0.01 |
| Grade 2: ECOG 2; KPS 60–70a | 78 (9) | 26 (7) | 52 (11) | 0.04 |
| Grade 3: ECOG 3, 4; KPS 10–50a | 39 (5) | 8 (2) | 31 (7) | <0.01 |
| Clinical characteristics during follow-up | ||||
| Distant metastasis, n (%) | 513 (29) | 120 (15) | 393 (42) | <0.01 |
| PS, last observed documentation, n (%) | 1249 (71) | 553 (68) | 696 (74) | <0.01 |
| Grade 1: ECOG 0, 1; KPS 80–100a | 990 (79) | 499 (90) | 491 (71) | <0.01 |
| Grade 2: ECOG 2; KPS 60–70a | 141 (11) | 34 (6) | 107 (15) | <0.01 |
| Grade 3: ECOG 3, 4; KPS 10–50a | 118 (9) | 20 (4) | 98 (14) | <0.01 |
| Hospice services, n (%) | 129 (7) | 21 (3) | 108 (12) | <0.01 |
| First course surgical resection, n (%) | 1029 (62) | 563 (72) | 466 (52) | <0.01 |
| Any chemo and hormonal therapies, n (%) | 1410 (80) | 595 (73) | 815 (86) | <0.01 |
| Alkylating agentsb | 547 (39) | 269 (45) | 278 (34) | <0.01 |
| Antimetabolitesb | 427 (30) | 113 (19) | 314 (39) | <0.01 |
| Antitumor antibioticsb | 452 (32) | 223 (38) | 229 (28) | <0.01 |
| Hormone therapyb | 594 (42) | 318 (53) | 276 (34) | <0.01 |
| Mitotic inhibitorsb | 761 (54) | 260 (44) | 501 (62) | <0.01 |
| Platinum agentsb | 512 (36) | 114 (19) | 398 (49) | <0.01 |
| Targeted therapiesb | 375 (27) | 124 (21) | 251 (31) | <0.01 |
| Otherc | 175 (10) | 48 (6) | 127 (13) | <0.01 |
Abbreviations: ECOG Eastern Cooperative Oncology Group, KPS Karnofsky PS, PS performance status, SD standard deviation, y year
aPercent of patients with any PS
bPercent of patients with any chemo or hormonal therapy
cOther treatments including immunotherapies and topoisomerases